MTOR and chronic myelogenous leukemia, BCR-ABL1 positive: We have shown that celecoxib is able to inhibit CML blast proliferation and survival, in vitro and in patient-derived cells, at therapeutically-relevant concentrations, through AMPK-dependent impairment of mTOR and β-catenin activity.